Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures. The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation. This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.…
Orthofix (OFIX) Upgraded to Buy: What Does It Mean for the Stock?
Orthofix Medical (NASDAQ: OFIX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,605 employees.
The shares were at 6.070 USD on 20 November 2026, down 58.7% over 52 weeks. Its 52-week range is 6.035 USD to 16.42 USD, and it trades at the bottom of that range.
Its market capitalisation is 247.41M USD.
Orthofix Medical reports return on equity of -20.5%, an operating margin of -2.1% and revenue up 1.1% year over year.
Its debt exceeds its cash by 175.76M USD, a debt-to-equity ratio of 0.40. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 10.00 USD is 64.7% above the current price. The next earnings report is expected on 23 February 2027.